Project Grant HT94252410889
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$1.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
The Department of the Army Medical Command, through the Military Medical Research and Development federal grant program (CFDA 12.420), awarded a $7,001,734 project grant to The University of Texas MD Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. This 4-year grant, which began on August 15, 2024 and will be completed by August 14, 2028, will support advanced cancer research initiatives at the premier...
The Department of the Army Medical Command awarded a $3,099,998 Project Grant to Wake Forest University Health Sciences under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research to develop targeted immunotherapy of breast cancer brain metastasis using chimeric antigen receptor macrophages. Through August 1, 2022 to July 31, 2025, the grantee will investigate medical solutions for the battlefield by transforming health care for service members and the...
The federal Project Grant award for $1,635,000.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research targeting the driver kinase PCTK1 in combination with ferroptosis inducers to combat breast cancer brain metastasis. The award was granted to The University of Texas M.D. Anderson Cancer Center, a premier academic cancer research and treatment institution, with a performance period from June 1, 2025 to May 31,...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,619,668 project grant to The University of Texas MD Anderson Cancer Center to inhibit brain metastases of HER2/neu-positive breast cancers using extracellular vesicles from renovated dendritic cells. The award began on May 1, 2024 and is scheduled for completion on April 30, 2027. The project aims to develop innovative treatments to improve outcomes for military service members and the...
The Department of the Army Medical Command awarded a $1,419,356 project grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2021 through September 2025 to develop novel immunotherapy approaches to suppress cancer metastasis and recurrence in bone. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...
The Department of the Army Medical Command awarded a $1,520,818 Project Grant to Southern Research Institute under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2022 to June 30, 2025 to develop rank signaling inhibitors for treating breast cancer bone metastasis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care through...
The University of Colorado Denver was awarded a $3,067,768 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420) to investigate the mechanisms underlying brain metastatic progression in ER+ breast cancer. The three-year award running from September 1, 2022 to August 31, 2025 will support research into medical solutions for the battlefield by transforming healthcare through innovative and impactful...
The University of Texas Health Science Center at Houston was awarded a $938,597 project grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to conduct research on peptides targeting metastatic tumor cells as probes for cancer detection and vehicles for therapy delivery. The three-year award beginning September 1, 2022 will support the development of new biomedical technologies using metastatic tumor-targeting peptides to...
The Department of the Army Medical Command awarded a $249,999 Project Grant to The University of Texas M.D. Anderson Cancer Center through the Military Medical Research and Development program. This three-year grant will fund research from September 2022 to August 2025 to revisit antiangiogenic therapy and target prostate cancer metabolism. The Military Medical Research and Development program, designated by CFDA #12.420, supports basic, applied, and advanced biomedical research with the goals...